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Abstract
Peptide vaccination for cancer immunotherapy requires identification of peptide epitopes derived from antigenic
proteins associated with tumors. Heparanase (Hpa) is broadly expressed in various advanced tumors and seems to
be an attractive new tumor-associated antigen. The present study was designed to predict and identify HLA-A2–
restricted cytotoxic T lymphocyte (CTL) epitopes in the protein of human Hpa. For this purpose, HLA-A2–restricted
CTL epitopes were identified using the following four-step procedure: 1) a computer-based epitope prediction
from the amino acid sequence of human Hpa, 2) a peptide-binding assay to determine the affinity of the predicted
protein with the HLA-A2 molecule, 3) stimulation of the primary T-cell response against the predicted peptides
in vitro, and 4) testing of the induced CTLs toward different kinds of carcinoma cells expressing Hpa antigens
and/or HLA-A2. The results demonstrated that, of the tested peptides, effectors induced by peptides of human
Hpa containing residues 525-533 (PAFSYSFFV, Hpa525), 277-285 (KMLKSFLKA, Hpa277), and 405-413 (WLSLLFKKL,
Hpa405) could effectively lyse various tumor cell lines that were Hpa-positive and HLA-A2-matched. We also found
that these peptide-specific CTLs could not lyse autologous lymphocytes with low Hpa activity. Further study re-
vealed that Hpa525, Hpa277, and Hpa405 peptides increased the frequency of IFN-γ–producing T cells compared
to a negative peptide. Our results suggest that Hpa525, Hpa277, and Hpa405 peptides are new HLA-A2–restricted
CTL epitopes capable of inducing Hpa-specific CTLs in vitro. Because Hpa is expressed in most advancedmalignant
tumors, Hpa525, Hpa277, and Hpa405 peptide–based vaccines may be useful for the immunotherapy for patients
with advanced tumors.
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Introduction
Malignant tumors are among the most lethal diseases threatening
humans. The therapeutic options for the treatment of patients with
carcinomas are limited to three fundamental modalities: surgical re-
section, chemotherapy, and radiation therapy. For especially ad-
vanced carcinomas, these modalities do not yield good results. For
the past few years, dendritic cell (DC)–based immunotherapy, which
has the advantages of strong immunogenicity, weak side effects, and
applicability, has become one of the hot topics in studies focused on
the therapies for malignant tumors.
One of tactics for tumor immunotherapy is the use of tumor-
associated antigen (TAA)–loaded DC. Dozens of TAAs have been
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described [1]. Unfortunately, the expression of most TAAs is restricted
to a few tumor types and to a fraction of patients with these types
of tumors, and the appearance of antigen-loss mutations in tumor
cells in response to immune pressure is well described [2,3]. To cir-
cumvent this issue, a class of TAAs termed universal tumor antigens
has been proposed that is hypothesized not only to trigger T cell re-
activity against a broad range of tumor types but also to play critical
functional roles in tumor growth and development. An ideal universal
TAA should have the following characteristics: 1) be expressed by the
majority of human cancers but rarely be expressed in normal tissues,
2) be indispensable in the process of tumorigenesis to avoid antigen
variation or depletion, 3) include peptide sequences that bind to major
histocompatibility complex (MHC) molecules, and 4) be recognized
by the T-cell repertoire in an MHC-restricted fashion to elicit specific
T-cell response [4,5].
Cytotoxic T lymphocytes (CTLs) are considered to be chief medi-
ators of tumor immunosurveillance through the recognition of TAAs
as cognate peptides bound to MHC molecules expressed on the sur-
face of tumor cells. A major achievement in tumor immunology for
the last 20 years has been the clear demonstration that CTL epitopes
binding to MHC rather than integral TAAs induce CTL reactions.
These epitope peptides are usually 8 to 10 amino acids long with 2 to
3 primary anchor residues that interact with the MHC class I mole-
cules and 2 to 3 amino acid residues that bind to the T-cell receptor
[6]. Therefore, the identification of CTL epitopes from TAAs has
become a critical step in the development of peptide-based immu-
notherapy for cancer.
Heparanase (Hpa) is the only endogenous endoglycosidase found
so far that can degrade the heparan sulfate proteoglycans in the ex-
tracellular matrix and basal membrane [7]. Unlike most other TAAs,
the expression of Hpa in tumor cells has been linked to tumor inva-
sion and metastasis. Heparanase can be found in almost all metastatic
malignant tumor cells. In normal tissue, it is only expressed in leu-
komonocytes and bone marrow. Inhibition of Hpa can obviously in-
hibit the proliferation and metastasis of tumor cells [8]. Activation of
Hpa is a determinant factor for the occurrence of metastasis, which
makes tumor cells break through the extracellular matrix and basal
membrane barrier, releases many kinds of cytokines, causes the for-
mation of new vessels, and causes the local permanent planting of
tumor cells [5,7–11]. Thus, Hpa is a potential universal TAA for
the treatment of advanced stage tumors. Our previous study demon-
strated that the DC-loaded full-length Hpa cDNA could induce an
Hpa-specific CTL, which showed potent lysis of gastric carcinoma
cells that were MHC-matched during Hpa expression, whereas it
had no effects on cells that were not MHC-compatible [12]. These
results indicate that Hpa can serve as a TAA that could be used for
tumor immunotherapy. Conversely, CTL epitopes must exist in the
Hpa protein that can induce specific CTL. Recently, Sommerfeldt
et al. [13] successfully predicted three epitopes derived from the
human Hpa amino acid sequence. Their results demonstrated that
these three epitopes could elicit Hpa-specific CTLs capable of lysing
breast cancer cells in vitro. Our previous study also demonstrated that
effectors induced by peptides of mouse Hpa at residue positions 398-
405 (LSLLFKKL, mHpa398) and 519-526 (FSYGFFVI, mHpa519)
could lyse three kinds of carcinoma cells expressing both Hpa and
H-2Kb (B16 melanoma cells, EL-4 leukoma cells, and Lewis lung can-
cer cells). In vivo experiments indicated that mHpa398 and mHpa519
peptides offered the possibility not only to immunize against tumors
but also to successfully treat tumor-bearing hosts [14].
On the basis of the analysis previously mentioned, the objective of
this study was mainly to find other possible HLA-A2–restricted CTL
epitopes in human Hpa with the ability to induce an Hpa-specific
antitumor immune response. For this purpose, we first predicted
candidate epitopes restricted by HLA-A2 in the protein of Hpa using
computer algorithms and molecular modeling. We then induced
Hpa-specific CTLs from HLA-A2-positive peripheral blood mono-
nuclear cells (PBMCs) from five healthy donors with these candidate
peptides in vitro to seek CTL epitopes present in the Hpa antigen.
We hope to find more Hpa epitopes capable of inducing an Hpa-
specific antitumor immune response and provide a foundation for
immunotherapy for patients with malignant tumors.
Materials and Methods
Cell Lines
The human TAP-deficient T2 cell line and BB7.2 cell line produc-
ing mAb against HLA-A2 were purchased from the American Type
Culture Collection (Manassas, VA). The osteogenic sarcoma cell line
U2OS (Hpa+,HLA-A2+) was purchased from Beijing Xiehe Medical
University (Beijing, China). The gastric cancer cell line KATO-III
(Hpa+,HLA-A2+), liver cancer cell line HepG2 (Hpa+,HLA-A2−),
breast cancer cell line MCF-7 (Hpa+,HLA-A2+), and colon cancer
cell line SW480 (Hpa+,HLA-A2+) were maintained in our laboratory.
U2OS cells were cultured in McCoy’s 5A medium (Life Technologies,
Inc., Gaithersburg, MD; Invitrogen, Carlsbad, CA) supplemented
with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 μg/ml
streptomycin, and 2 mM L-glutamine. BB7.2 cells were maintained
in DMEM containing 10% FCS, penicillin (100 U/ml), and strep-
tomycin (100 pg/ml). T2, KATO III, HepG2, MCF-7, and SW480
cells were all cultured in RPMI-1640 medium containing 10% FBS,
penicillin (200 U/ml), and streptomycin (100 μg/ml). All cell lines
mentioned previously were kept at 37°C in a humidified atmosphere
containing 5% CO2.
Epitope Prediction and Synthesizing
HumanHpa peptides withHLA-A2–bindingmotifs were predicted
by computer analysis as described previously [15,16]. Five nonapep-
tides derived from the human Hpa amino acid sequence and one
nonapeptide from HIV virus [HIVpol(476-484) (ILLEPVHGV)],
which served as a positive control in MHC peptide-binding assay
and a negative control in inducingHpa-specific CTL reactions in vitro,
were synthesized by the Beijing Scilight Biotechnology Ltd. Co.
(Beijing, China) with a purity >90% as determined by HPLC (Delta
600 Wasters Company). The molecular weight of the peptides was
validated by mass spectrum (API2000; PE, Waltham, MA). Lyophi-
lized peptides were dissolved in DMSO (Sigma) and stored at −20°C.
Molecular Modeling and Dynamics Calculation
Models of nonapeptides binding with HLA-A2.1 molecules were
established from the crystal structures of the MHC-I–peptide com-
plex in the Brookhaven Protein Data Bank: 3HLA for HLA-A2.1
and 3HSA for the nonapeptides. The HLA-A2.1 model was simpli-
fied by using only α1 and α2 domains with 18 water molecules
bound to them. Molecular mechanic and dynamic calculations were
performed using the Discover 3.0 package. The force field param-
eters used in this study were those of the consistent valence force
field. During the molecular dynamics and minimization calculation,
a dielectric constant of 1.0 was used. A 9-Å cutoff distance was
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applied to calculate the nonbinding interaction. The peptide ligand
was first relaxed by 2000 steps of conjugate gradient energy mini-
mization while maintaining the fixed protein. It was then submitted
to a 100-ps molecular dynamics calculation at 300 K. During these
100 ps, no protein atoms were allowed to move. The last confor-
mation was then solvated in a 10-Å-thick TIP3P water shell. Energy
minimization of the water shell followed by a 200-ps molecular
dynamics simulation of the fully solvated HLA-A2/ligand pair was
performed at 300 K. Finally, we obtained each of the candidate
peptide-MHC complex binding parameters, including nonbond en-
ergy, hydrogen bond number, and anchor residue distance.
HLA Stabilization Analysis
The synthesized peptides were used in an MHC stabilization assay
using T2 cells as described previously [17,18]. Briefly, T2 cells (2 ×
105) were incubated with 200 μl of RPMI-1640 containing 0.1%
FCS, 5 × 10−5 M β-mercaptoethanol, and each of the peptides at
a concentration of 10 μg/ml for 15 hours. After the incubation, sur-
face HLA-A2 molecules were stained with anti–HLA-A2 mAb (de-
rived from BB7.2 hybridoma culture supernatant) for 30 minutes at
4°C. T2 cells were washed twice with PBS and stained with fluores-
cein isothiocyanate–conjugated IgG antibodies for 30 minutes. The
cells were then rinsed three times with PBS and analyzed with a
FACScan (Becton Dickinson, San Jose, CA). The relative binding
affinity of the respective peptides was calculated from the mean fluo-
rescence intensities (MFIs) as follows: MFI(peptide) − MFI(unloaded cells)/
MFI(unloaded cells). Relative binding affinities >1.5 were considered
strong; 1.5 to 1.0, intermediate; and <1.0, low.
Dendritic Cell Generation from Human
Peripheral Blood Precursors
Dendritic cells from PBMCs were generated using the procedure
described by Romani et al. [19]. Briefly, PBMCs were isolated from
five healthy HLA-A2+ donors by Ficoll-Hypaque density gradient
centrifugation and then seeded into culture flasks in RPMI-1640
medium supplemented with penicillin (100 U/ml), streptomycin
(100 μg/ml), and 10% FBS. After monocytes adhered (incubation
for 2 hours), the nonadherent cells were collected and frozen in freeze
medium (60% RPMI-1640 and 30% FBS, 10% DMSO) for later
use in CTL assays. The adherent cells were cultured for 5 days in
RPMI-1640 containing 1000 U/ml of granulocyte–macrophage
colony-stimulating factor (R&D Systems, Inc., Minneapolis, MN)
and interleukin-4 (IL-4; R&D Systems, Inc.) and were the cultured
for an additional 2 days in the presence of 1000 U/ml of tumor ne-
crosis factor α (R&D Systems, Inc.) to induce final maturation. After
7 days of culture, the mature DCs were harvested and analyzed for
DC typical phenotypes by FACS analysis.
Reverse Transcription–Polymerase Chain Reaction
Total RNA of target cells (KATO-III gastric cancer cells, U2OS
osteogenic sarcoma cells, SW480 colonic cancer cells, MCF-7 breast
cancer cell line, MCF-7 cells transduced with full-length cDNA of
Hpa, HepG2 liver cancer cells) was isolated from cell extracts using
the Tripure RNA isolation kit (Roche, Basel, Switzerland) following
the manufacturer’s instructions. One microgram of total RNA was
reverse-transcribed, and the cDNA was amplified with Taq polymer-
ase (Takara, Dalian, China) using specific primers for Hpa (sense
primer: 5′-GAATGGCCCTACCAGGAGCA-3′ antisense primer:
5′-ACGCATTTAGGCCAAAGATCAAG-3′) or β-actin (sense primer:
5′-GTTGCGTTACACCCTTTCTTGACA-3′, antisense primer: 5′-
GCACGAAGGCTCATCATTCAAAA-3′). After initial denaturation
for 5 minutes at 94°C, the polymerase chain reaction thermal cycle
profile was 45 seconds at 94°C, 60 seconds at 66°C, and 60 seconds
at 72°C for 30 cycles, followed by a final extension for 5 minutes at
72°C. The products of Reverse Transcription–Polymerase Chain Re-
action (RT-PCR) were electrophoresed in a 1.5% agarose gel and visu-
alized by UVP after ethidium bromide staining.
Immunohistochemistry Staining
The previously mentioned target cells were cultured in six-well
culture dishes and fixed with 3.7% paraformaldehyde for 7 minutes
at room temperature. The dishes were then washed with buffer con-
taining 0.1 M Tris (pH 7.5), 1.5 M NaCl, and 1% BSA and were
permeabilized in the presence of 2% Triton X-100. Next, cells were
incubated with an Hpa antibody (0.5 μg/ml; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) for 1 hour at room temperature, washed, and
further incubated with secondary antibody. Finally, the cells were in-
cubated for 15 minutes with an avidin-biotin enzyme reagent. Slides
were immersed in DAB/H2O2 solution to develop the staining.
Phosphate-buffered saline was used as a negative control in place
of the primary antibody.
Induction of Peptide-Specific CTL with
Synthetic Hpa Peptides
The assay was done as described previously [20]. Briefly, DCs
were loaded with different Hpa peptides at a final concentration
of 100 μg/ml for 4 hours and were then irradiated with 20 Gy,
which prevented all outgrowths in the control cultures. Autologous
T cells were restimulated every 7 days with the previously mentioned
peptide-pulsed DCs to generate peptide-specific CTLs. Recombinant
interleukin 2 (IL-2) at a concentration of 20 U/ml was added to the
culture medium on day 3 after every stimulation. Cytotoxic T lym-
phocyte activity was then assessed on day 23 by a 4-hour 51Cr release
assay. Effectors generated from negative peptide-pulsed DCs were
used as controls.
Cytotoxicity Assay
To evaluate the levels of CTL activity, a standard 4-hour 51Cr
release assay was used as previously described [21]. Briefly, target
cells were incubated with 51Cr (100 μCi per 1 × 106 cells) for 2 hours
in a 37°C water bath. After incubation with 51Cr, target cells were
washed three times with PBS, resuspended in RPMI-1640 medium,
and mixed with effector cells at a 10:1, 20:1, 40:1, or 80:1 effector-
to-target (E/T) ratio. Assays were performed in triplicate for each
sample at each ratio in a 96-well round-bottomed plate. After a
4-hour incubation, the supernatants were harvested, and the amount
of released 51Cr was measured with a gamma counter. The percent-
specific lysis was calculated according to the following formula:
Specif ic lysis ¼ experimental release − spontaneous release
maximal release − spontaneous release
100%
Enzyme-Linked Immunospot Assay
IFN-γ secretion of effectors was assayed by enzyme-linked immu-
nospot (ELISPOT) [22]. Multiscreen 96-well assay plates (Dakewe,
Shenzhen, China) were precoated overnight at 4°C with anti–IFN-γ
antibody according to the manufacturer’s instruction. After washing
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with PBST (PBS–0.05% Tween 20), plates were blocked for 1 hour
at 37°C with PBS/1% BSA. Splenocytes were plated in triplicate
wells at a density of 2 × 105/100 μl in RPMI-1640 medium. For
restimulation, different peptides or medium alone was added. Plates
were cultured overnight, washed extensively with PBST, and incu-
bated with anti–IFN-γ mAb for 1 hour at 37°C. After washing, goat
antibiotin antibodies (Dakewe) were added, and the plated were in-
cubated for 1 hour at 37°C. Thirty microliters of activator solution
(Dakewe) was added to develop spots, and after 10 to 30 minutes,
the plates were washed with distilled water to stop the reaction. After
being air-dried, the number of spots in each well was counted using
the Bioreader 4000 PRO-X (Bio-Sys; Germany).
Results
Epitope Prediction and Molecular Modeling
The amino acid sequence of human Hpa was initially screened for
peptides containing the supermotif for HLA-A2. We chose five pep-
tides consisting of nine amino residues, which were found to contain
the supermotif for HLA-A2, as predicted epitopes of human Hpa.
These five peptides were all suitable HLA-A2–restricted CTL Hpa
epitopes as calculated by the quantitative motif method. The se-
quences of these peptides were PAFSYSFFV (525-533, Hpa525),
PLLSDTFAA (353-361, Hpa353), KMLKSFLKA (277-285,
Hpa277), PLPDYWLSL (400-408, Hpa400), and WLSLLFKKL
(405-413, Hpa405). Molecular modeling showed that these five po-
tential CTL epitopes fromHpamet the criteria for HLA-A2–restricted
CTL epitopes. As shown in Table 1, the peptides bound to the HLA-
A2 mode structure possessed a side chain of COOH-terminal anchor
residues oriented into the binding groove with different distances,
ranging from 17 to 20 Å.
Major Histocompatibility Complex Peptide-Binding Assay
The binding affinity of the previously mentioned five nonapeptides
to HLA-A2 was determined using antigen processing–deficient T2
cells due to their enhanced HLA-A2 expression when exposed to ex-
ogenous HLA-A2–binding peptides. An octapeptide mHpa(519-526)
(FSYGFFVI) derived from mouse Hpa and a nonapeptide HIVpol
(476-484) (ILLEPVHGV) derived from HIV served as negative and
positive controls, respectively. As shown in Table 2, all predicted pep-
tides were capable of up-regulating HLA-A2 molecular expression and
showed high affinity for HLA-A2.
Expression of Hpa and HLA-A2 in Target Cells
The expression of Hpa mRNA in all cell lines in this study was
analyzed by RT-PCR. The results demonstrated that Hpa mRNA
was detected in KATO-III gastric cancer cells, U2OS osteogenic sar-
coma cells, SW480 colonic cancer cells, and HepG2 liver cancer
cells. Meanwhile, Hpa mRNA could not be detected in MCF-7
breast cancer cells but could be detected in MCF-7 cells transduced
with the full-length cDNA of Hpa. Moreover, immunohistochemis-
try indicated the expression of Hpa protein in the cytoplasm of all
the mentioned target cells except MCF-7 cells (Figure 1).
We also detected HLA-A2 expression in all target cells in the study
by flow cytometry. The results indicated that the expression of HLA-
A2 in KATO-III gastric cancer cells, U2OS osteogenic sarcoma cells,
SW480 colonic cancer cells, or MCF-7 breast cancer cells was
90.0%, 86.8%, 73.8%, or 84.9%, respectively. Meanwhile, HLA-
A2 expression in HepG2 liver cancer cells was only 3.1%. After being
transfected with the plasmid of HLA-A2, the expression of HLA-A2
in HepG2/HLA-A2 cells was increased to 31.3%.
Identification of Hpa-Specific HLA-A2–Restricted CTL
Epitopes by Cytotoxicity Assay
To detect whether the predicted peptides could generate Hpa-
specific CTL in vitro, we used a standard 4-hour 51Cr release assay.
As shown in Figure 2, the three peptides (Hpa525, Hpa277, and
Hpa405) generated a highly specific 51Cr release at an E/Tratio from
40:1 to 80:1. These Hpa-specific CTLs caused greater than 40%
lysis of KATO-III gastric cancer cells, which were both hTERT-
and HLA-A2–positive at an E/T ratio of 80:1. However, the induced
effectors generated from Hpa353 and Hpa400 could not lyse the
mentioned target cells. Even at the highest E/T ratio, the lysis rate
was approximately 20%. We further assessed U2OS osteogenic sar-
coma cells and SW480 colonic cancer cells as target cells, both of
which also expressed Hpa and HLA-A2. The results demonstrated
that the CTLs induced by predicted peptides Hpa525, Hpa277,
and Hpa405 had significant killing effects on U2OS and SW480
Table 1. Characteristics of Hpa Candidate Epitope Bound to the Modeled HLA-A2.
Peptide Sequence Score Distance (Å) H-bond Number Nonbond Energy SAS of Anchor
Residue (Å)
P2 P9
Hpa(525-533) PAFSYSFFV 428.78 17.62 4 −17,158.9 3.6 4.9
Hpa(353-361) PLLSDTFAA 359.37 18.23 3 −16,144.5 15.6 18.7
Hpa(277-285) KMLKSFLKA 140.81 17.81 6 −19,237.5 5.4 6.98
Hpa(400-408) PLPDYWLSL 91.21 19.58 4 −16,276.2 2.9 8.7
Hpa(405-413) WLSLLFKKL 61.29 18.94 5 −18,324.7 3.7 4.6
Table 2. Analysis of HLA-A2–Binding Affinity of Hpa-Derived Peptides.
Name Sequence Position in Hpa Mean Fluorescence
Intensity
Fluorescence Index*,†
HIVpol
‡ ILLEPVHGV 476-484 912 ± 24.11 8.2
Hpa525 PAFSYSFFV 525-533 885 ± 9.17 7.1
Hpa353 PLLSDTFAA 353-361 895 ± 48.21 7.2
Hpa277 KMLKSFLKA 277-285 837 ± 88.39 6.67
Hpa400 PLPDYWLSL 400-408 762 ± 40.92 5.98
Hpa405 WLSLLFKKL 405-413 850 ± 47.57 6.79
mHpa519§ FSYGFFVI 519-526 115 ± 5.51 —
*Fluorescence intensity was calculatedwith the following formula: FI = [MFI(peptide) −MFI(unloaded cells)] /
MFI(unloaded cells).
†Fluorescence intensity was determined as high (FI > 1.5), intermediate (1.5 > FI > 1.0), or weak
(FI < 1.0).
‡HIVpol served as positive control.
§mHpa519 served as negative control.
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cells. Taken together, these results indicate that the predicted pep-
tides Hpa353, Hpa277, and Hpa405 could induce Hpa-specific
CTL responses in vitro and may be CTL epitopes of Hpa.
Specificity of CTLs Directed against Hpa
To further confirm the Hpa specificity of the CTLs, we took the
advantage of the HLA-A2–positive, Hpa-negative breast cancer cell
line, MCF-7 [13,23]. MCF-7 cells were transduced with pIRES2-
EGFP-Hpa plasmid, a eukaryotic fluorescent expression vector con-
taining the full-length cDNA of Hpa, by the DOTAP lipofection
method according to the manufacturer’s protocol [24]. After 24 hours
of transfection, 400 μg/ml G418 was added to the RPMI-1640
medium. After G418 selection for 4 weeks, drug-resistant indi-
vidual clones were randomly collected from the transfected cultures.
The selected clone was named MCF-7/Hpa. Reverse transcription–
polymerase chain reaction and immunohistochemistry demonstrated
Figure 1. Expression of Hpa in various target cells. (a) Expression of Hpa mRNA in various target cells. 1 indicates DNA marker; 2, KATO-
III; 3, SW480; 4, U2OS; 5, HepG2; 6, MCF-7; 7, MCF-7/Hpa. (b) Expression of Hpa protein in various target cells. A indicates KATO-III; B,
SW480; C , U2OS; D, HepG2; E , MCF-7; F , MCF-7/Hpa.
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that Hpa mRNA and protein was highly expressed in MCF-7/Hpa
cells but not in MCF-7 cells (Figure 1). Heparanase peptide–specific
CTLs were generated using peptide-pulsed DCs from four normal
HLA-A2–positive PBMC samples. After three stimulations, the cyto-
toxic activities of CTLs induced by Hpa525, Hpa277, and Hpa405
were determined against MCF-7 and MCF-7/Hpa cells at various
E/T ratios by the 51Cr release assay. As shown in Figure 3, these
Hpa-specific CTLs could lyse MCF-7/Hpa, whereas no obvious lysis
of MCF-7 was detected even at the highest E/T ratio. These results
clearly demonstrate that most CTLs were specifically targeted against
Hpa peptides that were presented in the context of HLA-A2.
Analysis of HLA-A2 Restriction
To further confirm that these CTL epitopes were restricted by
HLA-A2, we took advantage of the Hpa-positive, HLA-A2–negative
liver cancer cell line, HepG2 [25]. HepG2 cells were transduced with
a eukaryotic vector containing the full-length cDNA of HLA-A2
(given to us by Dr. Wan Y.) by the DOTAP lipofection method ac-
cording to the manufacturer’s protocol. After 24 hours of transduc-
tion, 400 μg/ml G418 was added to the RPMI-1640 medium. After
G418 selection for 4 weeks, drug-resistant individual clones were
randomly collected from the transduced cultures. The selected clone
was named HepG2/HLA-A2. HLA-A2 expression was 31.3% in
HepG2/HLA-A2, whereas it was 3.1% in HepG2 by flow cytometry
(data not shown). The 51Cr release assay showed that CTLs gener-
ated from Hpa525, Hpa277, or Hpa405 peptide-pulsed DCs could
lyse HepG2/HLA-A2. However, the previously mentioned induced
effectors could not lyse HepG2 cells, even at the highest E/T ratio
(Figure 3). These results clearly demonstrate that most CTLs are re-
stricted by HLA-A2.
Antibody Inhibition Assay
To further determine whether predicted peptide Hpa525-,
Hpa277-, and Hpa405-induced effectors recognized Hpa-positive
target tumor cells in an HLA-A2–restricted manner and whether
the effectors were derived from CD8+ T lymphocytes, mAbs against
HLA-A2 were used to block recognition of target cells and mAbs
against CD8 were used to block recognition of effectors. In addition,
mAbs against HLA-B0702 and mAbs against CD4 served as negative
controls. Results showed that after blocking the HLA-A2 sites on
the surface of target cells with HLA-A2 mAb or blocking the CD8
molecules on the surface of effector cells with CD8 mAb, the specific
killing effects of CTLs could be significantly eliminated (Figure 4).
However, mAbs of negative controls could not eliminate the kill-
ing effect of Hpa peptide–specific CTLs (data not shown). These re-
sults further indicate that the effectors are HLA-A2.1–restricted.
Moreover, these Hpa-specific CTLs are mainly raised from CD8+
T lymphocytes.
Killing Effect of Hpa-Specific CTLs on
Autologous Lymphocytes
While expressed in malignant tissues, Hpa could be also detected
at a low level in some normal cell and tissues. It was reported that
Hpa could be expressed in immunologically competent cells, natural
killer cells, and inflammatory cells such as neutrophils, granulocytes,
and activated T and B cells [12,14,26]. Theoretically, immunother-
apy aimed at Hpa may elicit adverse effects on the immune system.
To investigate the effect of Hpa-specific CTLs on immunologically
activated lymphocytes, CTLs induced by Hpa-specific peptides were
also used to lyse autologous lymphocytes and DCs. These results in-
dicate that Hpa peptide vaccinations had no detectable lysis effect on
autologous lymphocytes (Figure 2D).
Figure 2. Specific lysis of CTLsgenerated fromdifferent Hpa-derived
peptides against various target cells. Effector-to-target ratios are pre-
sented on the x-axis, whereas the y-axis represents the percent of
specific lysis. Cytotoxic T lymphocytes generated from HIV virus,
HIVpol(476-484) (ILLEPVHGV), served as a negative peptide (NP). (A)
Specific lysis of CTLs generated from Hpa525, Hpa353, Hpa277,
Hpa400, andHpa405 peptides against KATO-III. (B, C, andD) Specific
lysis of CTLs generated fromHpa525, Hpa277, and Hpa405 peptides
against SW480 (B), U2OS (C), and autologous lymphocytes (D).
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IFN-γ Secretion by ELISPOT
Because CTLs are known to produce the TH1 cytokine IFN-γ,
peptide-specific T cells were enumerated by measuring IFN-γ–
producing cells by ELISPOT assay. As shown in Figure 5, Hpa525,
Hpa277, and Hpa405 peptides were found to generate strong peptide-
specific T-cell responses by virtue of their ability to induce increased
frequencies of IFN-γ–producing T cells compared to negative pep-
tide (P < .05). These results suggest that Hpa peptide vaccines
could increase IFN-γ secretion by effectors and enhance the TH1 im-
mune response.
Discussion
For the past few years, the analysis of spontaneous immune re-
sponses to autologous tumors in cancer patients has allowed for
the identification of several categories of TAAs that can be targeted
by tumor-specific immune responses based on the recognition of tu-
mor antigens by CTL in an MHC-class I/peptide complex–restricted
manner [27,28]. Therefore, cancer-specific immunotherapy has be-
come a very attractive therapeutic approach against carcinomas.
Among these approaches, one of the most relevant for the develop-
ment of tumor immunotherapy is a peptide-based, cancer-specific
immunotherapy using universal TAAs, which are expressed by tumor
cells but not by most somatic adult tissues. Therefore, the identifica-
tion of T-cell epitopes from these antigens has become a critical step
in the development of peptide-based immunotherapy for cancers.
Peptide vaccination for cancer immunotherapy requires identifica-
tion of peptide epitopes derived from antigenic proteins associated
with the tumor. Such peptides can bind to MHC proteins (MHC
molecules) on the tumor cell surface, with the potential to initiate
a host immune response against the tumor. A breakthrough in the
identification of peptide epitopes was the elucidation that ligands
of a certain MHC molecule carry chemically related amino acids
in certain positions, leading to the definition of a peptide motif for
every MHC allele [29]. This knowledge was rapidly used to predict
potential epitopes from various antigens and initiated the so-called
reverse immunology, which has been the most successful strategy
for the identification of T-cell epitopes [30–32]. This approach in-
cluded a four-step procedure: 1) computer-based epitope prediction
from the amino acid sequence of a candidate antigen, 2) peptide-
binding assays to determine the affinity of the predicted peptide
for the MHC molecule, 3) the stimulation of the primary T-cell re-
sponse against predicted peptides in vitro, and 4) testing of the resul-
tant CTLs against target cells endogenously expressing the antigen
[12]. Using this approach, a number of T-cell epitopes have been
identified from several antigens such as hTERT [33,34], MAGE
[35,36], NY-ESO-1 [37], MUC-1 [38], and Ebola virus [16]. More-
over, with the elucidation of the crystal structures of human MHC
class I molecule HLA-A2, molecular modeling of HLA-A2–restricted
Figure 3. Study of the specificity and restriction of CTLs generated
from Hpa525, Hpa277, and Hpa405 epitopes. Effector-to-target ra-
tios are presented on the x-axis, whereas the y-axis represents the
percent of specific lysis. Cytotoxic T lymphocytes generated from
HIV virus, HIVpol(476-484) (ILLEPVHGV), served as a negative pep-
tide (NP). (A and B) Study of the specificity of CTLs generated from
Hpa525, Hpa277, and Hpa405 epitopes. MCF-7 cells, which were
HLA-A2–positive but Hpa-negative, were transduced with pIRES2-
EGFP-Hpa plasmid by the lipofection method. After 24 hours of
transfection and 4weeks of selectionwith G418, one drug-resistant
individual clone was randomly collected and was named MCF-7/
Hpa. The cytotoxic activity of CTLs induced by Hpa525, Hpa277,
and Hpa405 was determined against MCF-7 cells (A) and MCF-7/
Hpa cells (B) at various E/T ratios using the 51Cr release assay. (C
and D) Study of the restriction of CTLs generated from Hpa525,
Hpa277, and Hpa405 epitopes. HepG2 cells, which were Hpa-
positive but HLA-A2–negative, were transducedwith a plasmid con-
taining full-length cDNA of HLA-A2 by the lipofection method. After
24 hours of transfection and 4 weeks of selection with G418, one
drug-resistant individual clone was randomly collected and was
named HepG2/HLA-A2. The cytotoxic activity of CTLs induced by
Hpa525, Hpa277 and Hpa405 was determined against HepG2 cells
(C) and HepG2/HLA-A2 cells (D) at various E/T ratios using the 51Cr
release assay.
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epitopes became possible. Lim et al. [39] found that the peptides
bound to the HLA-A2 mode structure possess a side chain of a
COOH-terminal anchor residue oriented into the binding groove ex-
hibiting a specific distance, ranging from 15 to 21 Å, between the
two anchor residues.
It has been reported that most patients with advanced tumors
express Hpa. Specific inhibition of Hpa should reduce tumor an-
giogenesis and invasion [7,8,12,13]. More importantly, if a tumor
develops immune escape variants against Hpa-specific CTLs by
down-regulating Hpa expression, such variants might have reduced
angiogenic and invasive capacity. The high immunogenicity of Hpa
and its broad expression make this protein a very promising target for
tumor-specific vaccination strategies. If Hpa epitopes were presented
by different tumor cells and recognized by CTL, vaccines designed to
boost CTL responses against Hpa epitopes would be useful for clin-
ical therapy for advanced tumors. Although three HLA-A2–restricted
epitopes have been reported by Sommerfeldt et al. [13], we do not
know if there are other new HLA-A2–restricted epitopes existing in
the full-length amino acid sequence of Hpa.
In the present study, we first predicted candidate epitopes from
human Hpa antigen based on computer algorithms. Computational
methods combined with in vitro/in vivo studies have proven to be
very useful in the identification of immunogenic T cell epitopes
from defined antigens and pathogens [16,40]. In this study, 30
HLA-A2–restricted epitopes were predicted within the structural
proteins of human Hpa by supermotif combined with quantitative
motif. The five epitopes with the highest scores, Hpa(525-533)
(PAFSYSFFV), Hpa(353-361) (PLLSDTFAA), Hpa(277-285)
(KMLKSFLKA), Hpa(400-408) (PLPDYWLSL), and Hpa(405-
413) (WLSLLFKKL), were selected in this study. Interestingly, two
epitopes discovered by Sommerfeldt et al. [Hpa8-16(ALPPPLMLL),
Hpa16-24(LLLGPLGPL)] were also included in our predicted pep-
tides. Another epitope discovered by Sommerfeldt et al., Hpa183-
191 (DLIFGLNAL), is located very close to our predicted epitope
Hpa184-192 (LIFGLNALL) (data not shown). These results suggest
that the computer-based epitope prediction used in the present
study is effective and feasible. Second, we characterized the above
five predicted candidates by molecular modeling and found that
the above five peptides were suitable HLA-A2–restricted CTL epi-
topes. Third, the peptide-binding assay was used to determine the
affinity of every epitope with HLA-A2 and showed that the five epi-
topes had high affinity for the HLA-A2 molecule. Finally, we used a
standard 4-hour 51Cr release assay to determine the induction of CTLs
by every epitope. We found that only Hpa525, Hpa277, and Hpa405
could induce Hpa-specific immune responses. Further study demon-
strated that the antitumor immunity to KATO III gastric cancer cells,
MCF-7 breast cancer cells, SW480 colon cancer cells, U2OS osteo-
genic sarcoma cells, and HepG2 liver cancer cells induced by the above
three epitopes was Hpa-specific and HLA-A2–restricted. Thus, our
present study indicates that peptide Hpa(525-533) (PAFSYSFFV),
Hpa(277-285) (KMLKSFLKA), and Hpa(405-413) (WLSLLFKKL)
are new HLA-A2–restricted CTL epitopes capable of inducing Hpa-
specific CTLs in vitro. Because Hpa is expressed in most advanced
Figure 4. Inhibited recognition of induced cells by anti–HLA-A2 or
anti-CD8+ antibody. KATO-III target cells were incubated with or
without anti–HLA-A2 antibody from BB7.2 cells for 1 hour at 4°C.
Moreover, effectors induced by different Hpa-derived peptides
were also incubated with or without anti-CD8+ antibody for 1 hour
at 4°C. The cytotoxic activities of CTLs induced by Hpa525 (A),
Hpa277 (B) and Hpa405 (C) were determined against these KATO-
III cells at various E/T ratios using 51Cr release assay. T = target
cells; E = effectors.
Figure 5. IFN-γ–producing cells were enumerated by ELISPOT as-
say. Negative peptide (NP), HIVpol-derived from HIV virus, served
as a negative control. Phytohemagglutinin (PHA) served as a pos-
itive control. Column indicates mean; bars, SE. **Statistically sig-
nificant values at P < 0.01 using a paired Student’s t test were
assessed to compared with NP group.
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malignant tumors, the above threeHpa epitopes could contribute to the
design of epitope-based vaccines for patients with advanced cancers.
For the development of cancer vaccines, safety concerns still limit
their use in the future. Although Hpa expression is largely restricted
to cancer cells, it has been detected in activated immune cells, in-
cluding T and B cells, DCs, macrophages, neutrophils, and mast
cells, mediating extravasation and traffic to inflammatory sites
[8,12,41,42]. Consequently, any Hpa-based cancer vaccine therapy
will require assessment of potential adverse effects associated with
autoimmunity to cells and organs that are Hpa-positive. Our previ-
ous study showed that CTLs induced by DCs loaded with Hpa full-
length cDNA could not lyse autologous lymphocytes in vitro [12]. In
this study, to investigate the effects of Hpa peptide–specific CTLs on
immunologically activated lymphocytes, Hpa peptide–specific CTLs
were also used to lyse autologous lymphocytes. The results revealed
that Hpa peptide vaccination did not remarkably lyse these lym-
phocytes. It is conceivable that the level of Hpa expression in nor-
mal cells is below the threshold needed for recognition by these
Hpa peptide–specific CTL populations [9].
In conclusion, our results suggest that Hpa(525-533) (PAF-
SYSFFV), Hpa(277-285) (KMLKSFLKA), and Hpa(405-413)
(WLSLLFKKL) derived from human Hpa might be capable of in-
ducing HLA-A2–restricted CD8+ CTL, which would be a powerful
weapon in cancer-specific immunotherapy. Of course, several studies
have demonstrated that transduction of DCs with the entire TAA
gene could elicit more powerful immune responses than peptide-
pulsed DCs. This is because DCs transduced with the entire TAA
gene may present multiple epitopes including previously unknown
epitopes associated with different MHC class I molecules [21,43].
To overcome this shortcoming, we are now planning to evaluate im-
mune responses generated by several mixed epitopes of Hpa in vivo
and in vitro.
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